Dec 21, 2023
Shawn Hauser recently joined the “One Minute With…” podcast hosted by Jacques Santucci of Opus Consulting to discuss Vicente LLP’s history with cannabis legalization, the recent recommendation by the HHS to reschedule marijuana to a Schedule III drug and what this means for the future of federal drug policy reform. Listen now!
Nov 10, 2023
Federal and international law and policy insights, news and events from Vicente LLP.
By Jason Adelstone
Nov 6, 2023
While the cannabis industry in the United States awaits a marijuana scheduling decision from the DEA, many countries around the world continue to move forward with liberalizing their cannabis policies as a superior method of promoting the health and welfare of their citizens. In this blog post, we’ll take a closer look at five countries poised to make waves in the cannabis landscape in 2024, including Germany, Thailand, Colombia, the Czech Republic, and Switzerland.
Oct 26, 2023
This recorded session features members of Vicente LLP’s Federal and International Law and Policy practice group and London cannabis attorney Robert Jappie of Fieldfisher sharing insights into what’s happening with cannabis and hemp-derived cannabinoids across the pond and opportunities for US operators and investors.
By Jason Adelstone
Mar 15, 2023
In its 2022 report, the International Narcotics Control Board (INCB) argues that legalizing the non-medical and non-scientific use of cannabis has failed to achieve the benefits to society that were intended through such legalization. In its attempt to deliver evidence of this failure, INCB instead provides ample evidence to the contrary—that legalization and regulation work. Read this insight for Vicente LLP’s response to the annual report of the INCB.
By Shane Pennington
Nov 9, 2022
What outcomes are possible from the impending administrative process to reconsider cannabis’s schedule I status? What are the implications of those various possible outcomes? And how should we all proceed in light of it all?
By Shane Pennington
Oct 21, 2022
To appreciate the gravity of the President’s scheduling directive and what could happen next, you need to understand (1) how the administrative process the President has set in motion will actually work and (2) how the agencies in charge have used it to affirm and reaffirm cannabis’s schedule I1 status repeatedly throughout the Comprehensive Drug Abuse Prevention and Control Act of 1970’s (“CSA”) history. Those topics are covered in this article.
Jul 22, 2022
VS founding partner Christian Sederberg was recently interviewed by the Proud to Work in Cannabis podcast to discuss details regarding federal drug policy, as well as his own entrepreneurial background - from Amendment 64 to today.
By Jason Adelstone
Apr 27, 2022
A recent paper by Kenzi Riboulet-Zemouli argues that the 1961 Single Convention on Narcotic Drugs already allows for the regulation of Non-Medical cannabis. This premise, unfortunately, is just incorrect.
By Jonathan Cherkoss
Aug 30, 2021
Oregon voters passed two of the nation’s most sweeping drug policy reform measures in U.S. history in 2020, energizing grassroots organizers in Colorado and across the country. What's next for decriminalization and psychedelics reform in Colorado?
By Charles Alovisetti
Jan 25, 2021
Like anything in the cannabis industry, getting a debt deal done requires navigating unique regulatory challenges. Here are seven regulatory considerations that cannabis borrowers and lenders should keep in mind when pursuing a debt transaction.
By Charles Alovisetti, Elliot Choi, Sahar Ayinehsazian
Sep 18, 2020
Raising private capital continues to be a challenge for the nascent cannabis industry, but there are proactive steps companies can take to maximize the chance of a successful raise.